Literature DB >> 27567053

Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis.

E Sun Paik1, Minhee Shim1, Hyun Jin Choi1, Yoo-Young Lee2, Tae-Joong Kim1, Jeong-Won Lee1, Byoung-Gie Kim1, Duk-Soo Bae1, Chel Hun Choi3.   

Abstract

OBJECTIVE: To investigate the impact of pelvic and para-aortic lymphadenectomy during primary debulking surgery (PDS) on recurrence pattern and survival after recurrence in patients with advanced epithelial ovarian cancer (EOC) without suspected lymph node (LN) metastasis in preoperative imaging studies and intraoperative findings.
METHODS: A retrospective review of patients with FIGO stage III and IV EOC without suspected lymph node metastasis was performed. Patients with stage III EOC due to LN metastasis without peritoneal disease were excluded from this study. Survival comparisons for progression-free survival (PFS), overall survival (OS), and survival after recurrence were performed between patients with or without lymphadenectomy.
RESULTS: Of the 261 EOC patients fulfilling inclusion criteria, 194 (74.3%) experienced relapse and a further 132 (50.6%) died within a median follow-up period of 48months (range, 6-139months). Patterns of recurrence and CA-125 level at recurrence were not different between patients with lymphadenectomy and without lymphadenectomy; however, patients with lymphadenectomy showed longer survival after recurrence than those without lymphadenectomy (43 vs. 32months, p=0.013). This difference was pronounced in the group with residual tumor <1cm (48 vs. 30months, p=0.010). The survival advantage of lymphadenectomy after recurrence remained significant in multivariate analysis (HR 0.57, 95% CI 0.38-0.84, p=0.005).
CONCLUSIONS: Lymphadenectomy during PDS was associated with longer survival, especially survival after recurrence. The underlying mechanism should be elucidated in future studies.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lymphadenectomy; Ovarian neoplasm; Prognosis

Mesh:

Year:  2016        PMID: 27567053     DOI: 10.1016/j.ygyno.2016.08.321

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  A retrospective analysis of relapse-related factors for ovarian borderline tumors.

Authors:  Dan Ye; Haoran Shen; Wu Huang; Liangqing Yao
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

2.  The value of systematic lymphadenectomy during debulking surgery in the treatment of ovarian cancer: a meta-analysis of randomized controlled trials.

Authors:  Qingqing Lin; Wenchao Liu; Song Xu; Juan Li; Jinyi Tong
Journal:  J Ovarian Res       Date:  2020-05-08       Impact factor: 4.234

3.  Systematic Lymph Node Dissection May Be Abolished in Patients With Apparent Early-Stage Low-Grade Mucinous and Endometrioid Epithelial Ovarian Cancer.

Authors:  Jiayu Chen; Jie Yin; Yan Li; Yu Gu; Wei Wang; Ying Shan; Yong-Xue Wang; Meng Qin; Yan Cai; Ying Jin; Lingya Pan
Journal:  Front Oncol       Date:  2021-09-06       Impact factor: 6.244

4.  Survival Analysis of Lymph Node Resection in Ovarian Cancer: A Population-Based Study.

Authors:  Aoshuang Cheng; Jinghe Lang
Journal:  Front Oncol       Date:  2020-03-19       Impact factor: 6.244

5.  Lymphadenectomy for primary ovarian cancer: a systematic review and meta-analysis.

Authors:  Tatsuyuki Chiyoda; Manabu Sakurai; Toyomi Satoh; Satoru Nagase; Mikio Mikami; Hidetaka Katabuchi; Daisuke Aoki
Journal:  J Gynecol Oncol       Date:  2020-09       Impact factor: 4.401

6.  Effect of Waiting Time from Pathological Diagnosis to Definitive Concurrent Chemoradiation for Cervical Cancer on Overall Survival.

Authors:  Kyoung Won Noh; Bomi Kim; Chel Hun Choi; Tae-Joong Kim; Jeong-Won Lee; Byoung-Gie Kim; Duk-Soo Bae; Won Kyung Cho; Won Park; Yoo-Young Lee
Journal:  Cancer Res Treat       Date:  2021-04-15       Impact factor: 4.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.